1-3 of 3
arsenic trioxide
Close
Sort by
Journal Articles

Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study

Clinical Trials & Observations
Harinder Gill, Yammy Yung, Hiu-Tung Chu, Wing-Yan Au, Pui-Kwan Yip, Emily Lee, Rita Yim, Paul Lee, Daniel Cheuk, Shau-Yin Ha, Rock Y. Y. Leung, Edmond S. K. Ma, Cyrus R. Kumana, Yok-Lam Kwong
Journal: Blood Advances
Blood Adv (2021) 5 (14): 2829–2838.
https://doi.org/10.1182/bloodadvances.2021004789
Published: 2021
Includes: Supplemental data
Journal Articles

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Clinical Trials & Observations
Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1683–1689.
https://doi.org/10.1182/bloodadvances.2019001278
Published: 2020
Journal Articles

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD + AML

Silvia Masciarelli, Ernestina Capuano, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Francesca Liccardo, Martyna Śniegocka, Serena Travaglini, Nelida I. Noguera, Alessandra Picardi, Vincenzo Petrozza, Alessandro Fatica, Luca Tamagnone, Maria Teresa Voso, Francesco Lo Coco, Francesco Fazi
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4155–4160.
https://doi.org/10.1182/bloodadvances.2019000540
Published: 2019
Includes: Supplemental data